[Skip to Navigation]
Editorial
September 8, 2021

Early-Onset Atrial Fibrillation and Heritable Heart Disease—To Test or Not to Test?

Author Affiliations
  • 1Department of Medicine, Albert Einstein College of Medicine, Montefiore Medicine, Bronx, New York
  • 2The NUgene Project, Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
JAMA Cardiol. 2021;6(12):1359-1361. doi:10.1001/jamacardio.2021.3367

Atrial fibrillation (AF) is the most common sustained arrhythmia in humans, with an estimated 5.2 million patients in 2010 and a projection of more than 12 million being affected by 2030.1 The incidence and risk are progressive with age, with a cumulative risk of less than 5% in individuals younger than 55 years, with a lifetime risk of 37% influenced by clinical and genetic factors.2 This arrhythmia is a major source of morbidity and mortality worldwide, with a number of clinical risk factors, including hypertension, obesity, diabetes, sleep apnea, and myocardial, valvular, and arrhythmogenic heart diseases.

Add or change institution
×